CN110753546B - 治疗或预防急性肺损伤的化合物、组合物和方法 - Google Patents

治疗或预防急性肺损伤的化合物、组合物和方法 Download PDF

Info

Publication number
CN110753546B
CN110753546B CN201880039957.3A CN201880039957A CN110753546B CN 110753546 B CN110753546 B CN 110753546B CN 201880039957 A CN201880039957 A CN 201880039957A CN 110753546 B CN110753546 B CN 110753546B
Authority
CN
China
Prior art keywords
pazopanib
salt
subject
administration
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880039957.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN110753546A (zh
Inventor
D·吴
Q·袁
A·巴希特
W·唐
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of CN110753546A publication Critical patent/CN110753546A/zh
Application granted granted Critical
Publication of CN110753546B publication Critical patent/CN110753546B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201880039957.3A 2017-04-17 2018-04-17 治疗或预防急性肺损伤的化合物、组合物和方法 Active CN110753546B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762486232P 2017-04-17 2017-04-17
US62/486,232 2017-04-17
PCT/US2018/027980 WO2018195084A1 (en) 2017-04-17 2018-04-17 Compounds, compositions and methods of treating or preventing acute lung injury

Publications (2)

Publication Number Publication Date
CN110753546A CN110753546A (zh) 2020-02-04
CN110753546B true CN110753546B (zh) 2023-11-10

Family

ID=63856399

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880039957.3A Active CN110753546B (zh) 2017-04-17 2018-04-17 治疗或预防急性肺损伤的化合物、组合物和方法

Country Status (7)

Country Link
US (3) US11166953B2 (enExample)
EP (1) EP3612184B1 (enExample)
JP (1) JP7108018B2 (enExample)
CN (1) CN110753546B (enExample)
CA (1) CA3060247A1 (enExample)
IL (1) IL270070B2 (enExample)
WO (1) WO2018195084A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020386436A1 (en) * 2019-11-20 2022-05-26 Yale University Compounds, compositions, and methods for treating ischemia-reperfusion injury and/or lung injury
CN113350351A (zh) * 2020-03-13 2021-09-07 青晓制药公司 帕唑帕尼的应用、药物组合物、注射液及制备方法和应用
US20230181582A1 (en) * 2020-05-22 2023-06-15 Qx Therapeutics Inc. Compositions and methods for treating lung injuries associated with viral infections
CN113624978B (zh) * 2021-04-06 2023-09-19 四川大学华西医院 通过检测肺泡灌洗液及血清白蛋白来评估急性呼吸窘迫综合征/急性肺损伤及预后的试剂盒

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110142837A1 (en) * 2007-07-20 2011-06-16 Trustees Of The University Of Pennsylvania Method Of Treating Acute Respiratory Distress Syndrome
CN102869352A (zh) * 2010-04-27 2013-01-09 贝林格尔.英格海姆国际有限公司 治疗肿瘤及纤维变性疾病的新组合疗法
WO2015111947A1 (en) * 2014-01-24 2015-07-30 Lg Life Sciences Ltd. Composition for preventing or treating acute lung injury and acute respiratory distress syndrome

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
JPH07507059A (ja) 1992-03-25 1995-08-03 デポムド　システムズ，インコーポレイテッド アルキル置換セルロースをベースとする持続放出性経口薬剤投与剤形
AU3290397A (en) 1996-06-10 1998-01-07 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
EP0998271B3 (en) 1997-06-06 2014-10-29 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
AU781718B2 (en) 1999-11-02 2005-06-09 Depomed, Inc. Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
ATE340563T1 (de) 2000-02-04 2006-10-15 Depomed Inc DOSIERUNGSFORM DES TYPS ßHÜLLE UND KERNß MIT EINER WIRKSTOFFFREISETZUNG, DIE SICH DER NULLTEN ORDNUNG ANNÄHERT
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6451808B1 (en) 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
EP1343782B1 (en) 2000-12-21 2009-05-06 SmithKline Beecham Corporation Pyrimidineamines as angiogenesis modulators
EP1401423A4 (en) 2001-05-29 2006-08-16 Depomed Dev Ltd METHOD FOR THE TREATMENT OF GASTROÖSOPHAGEAL REFLUX DISEASE AND NURSING ACID BREAKDOWN
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US7413751B2 (en) 2001-10-25 2008-08-19 Depomed, Inc. Methods of treatment using a gastric retained losartan dosage
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
WO2008080153A2 (en) * 2006-12-22 2008-07-03 The Children's Hospital Of Philadelphia A novel protein kinase c therapy for the treatment of acute lung injury
EP2259844A4 (en) 2008-03-05 2012-02-01 Vicus Therapeutics Llc COMPOSITIONS AND METHODS FOR MUCOSITIS AND ONCOLOGICAL THERAPIES
JP2014503500A (ja) * 2010-11-18 2014-02-13 シンタ ファーマスーティカルズ コーポレーション 低酸素状態に基づく酸素感受性薬剤による治療に適した被験体の事前選択
MY181439A (en) * 2011-02-28 2020-12-22 Sunshine Lake Pharma Co Ltd Substituted quinoline compounds and methods of use
CN104254249B (zh) * 2011-10-31 2017-02-15 诺华股份有限公司 帕唑帕尼制剂
WO2013148537A1 (en) * 2012-03-29 2013-10-03 Ning Xi Substituted spirobicyclic compounds and methods of use
US20150044288A1 (en) 2013-07-31 2015-02-12 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
EP3052480B1 (en) * 2013-09-30 2020-11-11 The Texas A & M University System Compositions associated with and methods of managing neutrophil movement
US9718841B2 (en) * 2014-04-22 2017-08-01 Calitor Sciences, Llc Bicyclic pyrazolone compounds and methods of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110142837A1 (en) * 2007-07-20 2011-06-16 Trustees Of The University Of Pennsylvania Method Of Treating Acute Respiratory Distress Syndrome
CN102869352A (zh) * 2010-04-27 2013-01-09 贝林格尔.英格海姆国际有限公司 治疗肿瘤及纤维变性疾病的新组合疗法
WO2015111947A1 (en) * 2014-01-24 2015-07-30 Lg Life Sciences Ltd. Composition for preventing or treating acute lung injury and acute respiratory distress syndrome

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Effect of Nilotinib on Bleomycin-Induced Acute Lung Injury and Pulmonary Fibrosis in Mice;Chin Kook Rhee et al;《Respiration》;20111231;第82卷;第273-287页，尤其是摘要 *
Siglec-E Promotes _2-Integrin-dependent NADPH Oxidase Activation to Suppress Neutrophil Recruitment to the Lung;Sarah J.McMillan et al;《The Journal of biological chemistry》;20140718;第289卷(第29期);第20370-20376页，尤其是摘要，第20373页左栏讨论，第20375页图5 *

Also Published As

Publication number Publication date
US11166953B2 (en) 2021-11-09
WO2018195084A1 (en) 2018-10-25
US11890283B2 (en) 2024-02-06
US20210121459A1 (en) 2021-04-29
IL270070B1 (en) 2023-05-01
CN110753546A (zh) 2020-02-04
EP3612184A4 (en) 2021-01-20
IL270070B2 (en) 2023-09-01
JP7108018B2 (ja) 2022-07-27
JP2020516689A (ja) 2020-06-11
CA3060247A1 (en) 2018-10-25
US20240165115A1 (en) 2024-05-23
EP3612184A1 (en) 2020-02-26
IL270070A (enExample) 2019-12-31
EP3612184B1 (en) 2024-06-05
US20220040177A1 (en) 2022-02-10

Similar Documents

Publication Publication Date Title
US11890283B2 (en) Compounds, compositions and methods of treating or preventing acute lung injury
Strand et al. Innate immune signaling induces expression and shedding of the heparan sulfate proteoglycan syndecan‐4 in cardiac fibroblasts and myocytes, affecting inflammation in the pressure‐overloaded heart
JP6778681B2 (ja) Ｈｍｇｂ１媒介性炎症の治療
Chen et al. Dependence of fibroblast infiltration in tumor stroma on type IV collagen-initiated integrin signal through induction of platelet-derived growth factor
Trinh et al. Characterization of cysteinyl leukotriene-related receptors and their interactions in a mouse model of asthma
US8252807B2 (en) Methods of inhibiting the interaction between S100 and the receptor for advanced glycation end-products
US20230026808A1 (en) Compounds, compositions, and methods for treating ischemia-reperfusion injury and/or lung injury
Gao et al. Interaction of N‐acetyl‐seryl‐aspartyl‐lysyl‐proline with the angiotensin‐converting enzyme 2–angiotensin‐(1–7)–Mas axis attenuates pulmonary fibrosis in silicotic rats
Wang et al. Rosuvastatin attenuates atrial structural remodelling in rats with myocardial infarction through the inhibition of the p38 MAPK signalling pathway
CN108159423A (zh) 治疗和预防心血管疾病的组合物和方法
KR20170036928A (ko) IKKε 억제제를 유효성분으로 함유하는 만성 부비동염 예방 또는 치료용 약학조성물
TW202128212A (zh) 一種具緩解抗癌藥物抗藥性及增加抗癌藥物敏感性之醫藥組合物及其用途
HK40018465A (en) Compounds, compositions and methods of treating or preventing acute lung injury
HK40018465B (zh) 治疗或预防急性肺损伤的化合物、组合物和方法
US11026945B2 (en) Protein kinase RNA-like endoplasmic reticulum kinase (PERK) inhibitors for prevention and/or treatment of lung injury and/or inflammation
HK40079687A (en) Compounds, compositions, and methods for treating ischemia-reperfusion injury and/or lung injury
He A novel prophylactic strategy to minimize stem cell transplantation-related complications
US9801840B1 (en) Pharmaceutical composition and use thereof
Ngwa Targeting Vascular Endothelial Glutaminase in Triple Negative Breast Cancer
RU2663929C2 (ru) Использование производного соединения тиохромено[2,3-с]хинолин-12-она для лечения немелкоклеточного рака легких
Wu et al. Macrophage PD-1 regulates energy expenditure and metabolic dysfunction under immune checkpoint blockade
TW201627006A (zh) 使用抗－ｃｄ４４中和抗體來治療和／或預防心房顫動
Rounds et al. Articles in PresS. Am J Physiol Lung Cell Mol Physiol (March 3, 2017). doi: 10.1152/ajplung. 00393.2016
Koch The role of MYD88-dependent receptors in the anti-tumor efficacy of the EGFR inhibitor Erlotinib in head and neck cancer
Hegeman Ventilator-induced lung injury: pathogenesis & therapeutic interventions

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40018465

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant